Change in pharmacokinetics Sample Clauses

Change in pharmacokinetics. Re- sults of pharmacokinetics measure- ments (i.e., biotransformation, extent of absorption, tissue distribution, and excretion) obtained in rats receiving the single inhalation exposure to the low dose of the test substance (Group B) shall be compared to the cor- responding results obtained in rats re- ceiving repeated inhalation exposures to the low dose of the test substance (Group F).
AutoNDA by SimpleDocs
Change in pharmacokinetics. R e- s u l t s of p h a r m a co k i n e t ics m e a s ur e- m e n t s ( i . e., bio t r a n sfo r m a t io n , ex t e n t of a bso r p t io n , t iss u e dis t r ib u t io n , a n d exc r e t io n) ob t a i n ed i n r a t s r eceivi n g t h e s i n gle i nh a l a t io n expos ur e t o t h e low dose of t h e t es t s u bs t a n ce ( G r o u p B) s h a ll be co m p a r ed t o t h e co r - r espo n di n g r es u l t s ob t a i n ed i n r a t s r e- ceivi n g r epe a t ed i nh a l a t io n expos ur es t o t h e low dose of t h e t es t s u bs t a n ce ( G r o u p F ).

Related to Change in pharmacokinetics

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!